ライフサイエンスコーパス: tumor suppressor

1 l pyruvate carrier 1 (MPC-1) appears to be a tumor suppressor.

2 uently mutated in cancers and functions as a tumor suppressor.

3 genous GLS2, defying its role as a bona fide tumor suppressor.

4 e regulator of Ras signaling and a potential tumor suppressor.

5 ajority of NF2 patients show loss of the NF2 tumor suppressor.

6 Here we report ZAP as a genuine tumor suppressor.

7 ally regulates cell signaling and is a human tumor suppressor.

8 ligase involved in Parkinson's disease, is a tumor suppressor.

9 ble strand break repair, thereby acting as a tumor suppressor.

10 stigated whether DCC could act as a melanoma tumor suppressor.

11 an patients implicating Fbxl8 functions as a tumor suppressor.

12 xenografts, suggesting that RBM10 acts as a tumor suppressor.

13 tworks, including those governed by the TP53 tumor suppressor.

14 a, further supporting that DCC is a melanoma tumor suppressor.

15 rkie transcription coactivator and the Warts tumor suppressor.

16 to deletion or amplification of oncogenes or tumor suppressors.

17 through altered expression of oncogenes and tumor suppressors.

18 s function as oncogenes and some function as tumor suppressors.

19 RNA expression levels of proto-oncogenes and tumor suppressors.

20 iquitination of novel targets, including key tumor suppressors.

21 lled by the circadian clock are oncogenes or tumor suppressors.

22 nterrupt Grb2-SOS1 association, can serve as tumor suppressors.

23 ther yet-to-be-characterized potential ccRCC tumor-suppressors.

24 regulation of the Hippo pathway kinase large tumor suppressor 2 (LATS2) and yes-associated protein (Y

25 As a tumor suppressor, A20 directly inhibits IKK activation a

26 effects on MBNL1 may therefore, yield potent tumor suppressor activities, uncovering new therapeutic

27 These findings demonstrate that p53 tumor suppressor activity is reduced by DNA-binding doma

28 afts, while a subset had clinically relevant tumor-suppressor activity.

29 red 25 years ago as a binding partner of the tumor suppressor adenomatous polyposis coli (APC) [1]; h

30 The tumor suppressor adenomatous polyposis coli (APC) is fre

31 rectal cancers (CRC) through mutation of the tumor suppressor Adenomatous Polyposis Coli (APC).

32 ATM kinase is a tumor suppressor and a master regulator of the DNA damag

33 of loading-conditioned urine as a potential tumor suppressor and a source of diagnostic biomarkers.

34 stimulating protein of p53 2 (ASPP2), a host tumor suppressor and an important CagA target, contribut

35 = 0.0028), which has been reported as both a tumor suppressor and an oncogene.

36 p53 is a potent tumor suppressor and commonly mutated in human cancers.

37 us polyposis coli (APC), a protein with both tumor suppressor and cytoskeletal functions, concentrate

38 icant fold increase in the levels of several tumor suppressor and DNA repair gene protein products (G

39 The tumor suppressor and FERM domain protein Neurofibromin 2

40 In addition, Klotho is also a tumor suppressor and has beneficial roles in multiple or

41 r findings reveal that RGS12 is an essential tumor suppressor and highlights RGS12 as a potential the

42 is regulated by the von Hippel-Lindau (VHL) tumor suppressor and is highly expressed in clear cell r

43 Tumor suppressor and kinase STK11 (also called LKB1) reg

44 d DNA damage sites, DNA2 functions as both a tumor suppressor and promoter.

45 We report that neurofibromin, a tumor suppressor and Ras-GAP (GTPase-activating protein)

46 These findings indicate that KMT2D is a lung tumor suppressor and that KMT2D deficiency confers a the

47 nregulation of oncogenes and upregulation of tumor suppressors and apoptosis.

48 Importantly, ABHD5 also functions as a tumor suppressor, and ABHD5 mRNA expression levels corre

49 NF2 is a well-established tumor suppressor, and loss of NF2 severely compromises H

50 cancer development, occurring in oncogenes, tumor suppressors, and dual role genes.

51 wn path to colorectal cancer through loss of tumor suppressors APC and TP53 and gain of the KRAS onco

52 UNC5B and PP2A are regarded as tumor suppressors, as they promote apoptosis and are del

53 re, we describe a mechanism by which the ARF tumor suppressor binds PPM1G to negatively regulate its

54 ticular, we found that the co-binding of the tumor suppressor BRCA1 and RNA polymerase II, a well-kno

55 DNA helicase and interacting partner of the tumor suppressor BRCA1, is crucial for the repair of DNA

56 The tumor suppressor BRCA2 plays a key role in initiating ho

57 e transcription factor p53 is the best-known tumor suppressor, but its sibling p63 is a master regula

58 well-established role in inhibiting the p53 tumor suppressor by binding to MDMX and stimulating MDMX

59 findings suggest that GRK2 can function as a tumor suppressor by inhibiting MALT1 and provide a roadm

60 ed miRNA, namely EBV-miR-BART6-3p, acts as a tumor suppressor by inhibiting metastasis and invasion.

61 Protein Phosphatase 2A (PP2A) functions as a tumor suppressor by negatively regulating multiple oncog

62 HIF1A can act a tumor suppressor by preventing the expression of PPP1R1B

63 RNA-binding protein ZFP36L1 functions as a tumor suppressor by regulating the mRNA stability of a n

64 idate the clinical relevance of new putative tumor suppressors by showing these are frequently altere

65 paracrine stimulation, and suggest that this tumor suppressor can promote early premalignant epiderma

66 omodomain-containing protein BRD9 and glioma tumor suppressor candidate region 1 (GLTSCR1) or its par

67 Human (Homo sapiens) glioma tumor-suppressor candidate region gene2 (GLTSCR2) and ye

68 The tumor suppressor CDK10 was deleted in 80% of the cohort

69 -inflammatory functions, miR-146a is a known tumor suppressor commonly deleted or expressed at reduce

70 y identifies a new multiple myeloma-specific tumor suppressor complex that regulates autophagy and un

71 The PTEN tumor suppressor controls cell death and survival by reg

72 p27 is an atypical tumor suppressor-deletion or mutational inactivation of

73 this study, we demonstrate that in OCSC, the tumor suppressor disabled homolog 2-interacting protein

74 Prior candidate gene studies have shown tumor suppressor DNA methylation in breast milk related

75 showed that medulloblastomas lacking the p53 tumor suppressor do not express surface MHC-I and are th

76 protein O1 (FOXO1) is considered to be a key tumor suppressor due to its involvement in a broad range

77 ed by Ptpn2, has been shown to function as a tumor suppressor during skin carcinogenesis.

78 part through an epigenetic activation of the tumor-suppressor ERRFI1 in response to OSMI-1 treatment.

79 Interestingly, STXBP4 is a potential tumor suppressor for human kidney cancer, whose downregu

80 Oncogene activation and loss of tumor suppressor function changes the metabolic activity

81 Mdm2 targeting plays a predominant tumor suppressor function in wild-type TP53 contexts, wh

82 ur results reveal a previously unappreciated tumor suppressor function of FTO in ovarian CSC mediated

83 ngs provide a novel mechanism regulating the tumor suppressor function of TGFbeta in liver carcinogen

84 A new tumor suppressor function of the RNA demethylase FTO imp

85 Consistent with the tumor suppressor function of UBR5 (HYD) in Drosophila, H

86 3) either directly lose wildtype p53 (wtp53) tumor suppressor function or exhibit a dominant negative

87 These findings demonstrate that BRCA2 tumor suppressor function tolerates substantial reductio

88 to decrease function of oncogenes, increase tumor suppressor function, and enhance immune function.

89 PP2A dephosphorylation site specificity and tumor suppressor function.

90 on von Hippel-Lindau (VHL) ubiquitin ligase tumor suppressor function.

91 The p53 tumor suppressor functions as a tetrameric transcription

92 p53 transcription factor confers its potent tumor suppressor functions primarily through the regulat

93 has led to the hypothesis that it may exert tumor suppressor functions.

94 f site-specific dephosphorylation and of its tumor suppressor functions.

95 B1 (LKB1) has been studied extensively as a tumor suppressor gene (Stk11) in the context of cancer.

96 homolog located on chromosome 10 (PTEN) is a tumor suppressor gene and one of the most frequently mut

97 conclusion, FRMD6 was identified as a novel tumor suppressor gene and prognostic biomarker candidate

98 e findings herein identify TMIGD1 as a novel tumor suppressor gene and provide new insights into the

99 Lung tumor suppressor gene Gprc5a-knockout (ko) mice are susc

100 We conclude that ERbeta is a tumor suppressor gene in the VP and MG where its loss in

101 X functions as a medulloblastoma oncogene or tumor suppressor gene is not known.

102 cer 2 (BRCA2) (PALB2) has emerged as a major tumor suppressor gene linked to breast cancer (BC), panc

103 s, alterations in epigenetic regulators, and tumor suppressor gene mutation.

104 rly gene downregulated the expression of the tumor suppressor gene N-myc downstream-regulated gene 1

105 Primary PCa with deletion of the tumor suppressor gene PTEN (PTEN-del) can be modeled thr

106 tably, CDCP1 cooperates with the loss of the tumor suppressor gene PTEN to promote the emergence of m

107 atterning, cell fate determination, and as a tumor suppressor gene that restricts cell lineage progre

108 Notably, the HIC1 tumor suppressor gene was stimulated by JMJD1A and MDFIC

109 d a chromosome 17p loss, containing the TP53 tumor suppressor gene, that was significantly associated

110 chastically be selected for when targeting a tumor suppressor gene, we could effectively recapitulate

111 howing loss of the Neurofibromatosis 2 (NF2) tumor suppressor gene.

112 unique 5-hmC in the promoter region of MGMT tumor suppressor gene.

113 ng from two hits to the same allele of PLCD1 tumor suppressor gene.

114 ations in the neurofibromatosis type 1 (NF1) tumor suppressor gene.

115 tumors, confirming the role of ADAMTS12 as a tumor suppressor gene.

116 tion syndrome caused by mutations in the NF1 tumor suppressor gene.

117 er-associated mutants that arose in the DLC1 tumor suppressor gene.

118 phospholipase C delta 1 (PLCD1), a proposed tumor suppressor gene.

119 an unusual example, where inactivation of a tumor-suppressor gene and activation of an oncogene are

120 e MYCN oncogene and inactivation of the ATRX tumor-suppressor gene correlate with high-risk disease a

121 er was generated through the deletion of the tumor-suppressor gene Trp53 in conjunction with oncogeni

122 ed cell death 4 (PDCD4) is a proinflammatory tumor-suppressor gene which helps to prevent the transit

123 is the most frequently mutated, well-studied tumor-suppressor gene, yet the molecular basis of the sw

124 methylation and gene silencing of hemizygous tumor suppressor genes (TSG), we thus hypothesized that

125 ancer initiation through inactivation of two tumor suppressor genes and activation of one oncogene, a

126 omas in WT mice via in utero deletion of key tumor suppressor genes and serially monitored cortical e

127 mutations can be exploited to identify novel tumor suppressor genes and to obtain a deeper characteri

128 a DNMT1 inhibitor, induces re-expression of tumor suppressor genes by removing/erasing methylation m

129 RISPR-Cas9 system to model loss of candidate tumor suppressor genes in SCLC, and we anticipate that t

130 lation ITH mapping to gene promoter areas or tumor suppressor genes is low.

131 -5p as a Sox2-induced miRNA that targets the tumor suppressor genes PTEN and FoxO1 and regulates the

132 MFS and UPS frequently lose function of the tumor suppressor genes RB1 and TP53 In this issue of Can

133 copy number alterations or mutations in the tumor suppressor genes RB1 and TP53.

134 emness to miR-486-5p-dependent modulation of tumor suppressor genes that feeds back to regulate gliom

135 Here we report that inactivation of tumor suppressor genes Trp53 and Rb1 in the gastric squa

136 al acquisition of mutations in oncogenes and tumor suppressor genes, as well as changes in the pancre

137 ning gene partners that are known oncogenes, tumor suppressor genes, COSMIC genes, and/or transcripti

138 e further curated VIS-involved oncogenes and tumor suppressor genes, virus-host interactions involved

139 e/threonine phosphatases are important human tumor suppressor genes.

140 etic and epigenetic changes in oncogenes and tumor suppressor genes.

141 on about their combined role as oncogenes or tumor suppressor genes.

142 uishing passenger genes, oncogenes (OGs) and tumor-suppressor genes (TSGs) for each cancer type is cr

143 mall changes in the RT rate or set of driver tumor-suppressor genes (TSGs) were observed to alter the

144 ome, which sometimes leads to the removal of tumor-suppressor genes, and can induce complex transloca

145 etic aberrations that result in silencing of tumor-suppressor genes, oncogene addictions, and enhance

146 cantly overrepresented in anti-longevity and tumor-suppressor genes, while genes inhibiting cellular

147 ling oncogenes and inactivating mutations in tumor-suppressor genes.

148 transcriptional repression, mainly targeting tumor-suppressor genes.

149 These findings reveal that mutation of the tumor suppressor HACE1 disrupts its role as a regulator

150 mitant with an upregulation of caspase 3 and tumor suppressors i.e., p53, MEG3 and GAS5, in U251 cell

151 von Hippel-Lindau (VHL) is a critical tumor suppressor in clear cell renal cell carcinomas (cc

152 emonstrate in vivo that, despite acting as a tumor suppressor in healthy alveolar progenitor cells, p

153 s a master regulator of liver function and a tumor suppressor in hepatocellular carcinoma (HCC).

154 the multifunctional cue netrin-1, acts as a tumor suppressor in intestinal cancer and lung metastasi

155 l tumor grade, establishing this kinase as a tumor suppressor in liver cancer.

156 Our findings establish IL-17RD as a tumor suppressor in mice and suggest that the protein ex

157 ase 10 (HDAC10) might function as a putative tumor suppressor in mice carrying a spontaneously activa

158 DNA repair in human cells and functions as a tumor suppressor in mice.

159 , emerging evidence demonstrate that it is a tumor suppressor in more complex carcinogenic processes.

160 This study identifies HRK as a novel tumor suppressor in neuroblastoma and suggests dual MEK

161 ed retinoic acid-induced gene G (Rig-G) as a tumor suppressor in not only acute promyelocytic leukemi

162 CA1-associated protein (BAP1) functions as a tumor suppressor in pancreatic cancer by promoting the a

163 of both KRAS mutation and loss of the CDKN2A tumor suppressor in PDAC, clinical and preclinical studi

164 findings reveal a novel role for PADI4 as a tumor suppressor in regulating breast cancer stem cells

165 , our results establish the role of YAP as a tumor suppressor in the adult colon and implicate Hippo

166 ely, our study demonstrates that DEPTOR is a tumor suppressor in the prostate, and its depletion prom

167 We discover inactivation of tumor suppressors in intron regions and that tissue type

168 HIF1alpha has been termed a tumor-suppressor in clear cell renal cell carcinoma (ccR

169 f 14q deletion in ccRCC and that it is not a tumor-suppressor in this malignancy.

170 any transcripts affecting core oncogenic and tumor suppressors, including cyclin D2 and PTEN.

171 However, another tumor suppressor, inositol-polyphosphate 4-phosphatase t

172 Although well recognized as a tumor suppressor, involvement of PTEN mutations in media

173 Loss of the von Hippel-Lindau (VHL) tumor suppressor is a hallmark feature of renal clear ce

174 miR-185 functions as a tumor suppressor: its restored expression impaired survi

175 pendent translation of the mRNA encoding the tumor suppressor JUND.

176 hat beta-HPV 8E6 reduced activation of large tumor suppressor kinase (LATS), an HP kinase.

177 orylation of the hippo effector kinase large tumor suppressor kinase-1 and reduces nuclear accumulati

178 regulator of the hippo effector kinase large tumor suppressor kinase-1 and regulate ovarian tumor gro

179 FBXW7 targeted the frequently inactivated tumor suppressor KMT2D for protein degradation, subseque

180 n BAP1-deficient pancreatic tumors, with the tumor suppressor LATS exhibiting enhanced ubiquitin-depe

181 how that genetic deficiency of Folliculin, a tumor suppressor, leads to misconnection of blood and ly

182 pon disruption of the Bap1, Nf2, and Cdkn2ab tumor suppressor loci in various combinations as also fr

183 cell cycle machinery and loss of the CDKN2A tumor suppressor locus make CDK4/6 a potential target in

184 rofiles uncovered novel associations between tumor suppressor loss and targetable kinases.

185 ty in vitro We conclude that loss of DAB2, a tumor suppressor, may enhance myosin VI-mediated transcr

186 telomere shortening is currently viewed as a tumor suppressor mechanism and should protect from cance

187 Cellular senescence is a potent tumor suppressor mechanism but also contributes to aging

188 We found that H. pylori compromises key tumor suppressor mechanisms: the host stress and apoptot

189 sets of microRNAs include both oncogenic and tumor suppressor microRNAs.

190 A novel tumor suppressor miR-1185-1 is involved in molecular reg

191 According to TCGA data, the tumor suppressor miR-200b is overedited in thyroid tumor

192 Tumor suppressor miRNAs may hold therapeutic promise but

193 lastoma risk-associated locus 6p22.3-derived tumor suppressor NBAT1 is a p53-responsive lncRNA that r

194 aused by germline pathogenic variants in the tumor suppressor NF2.

195 NR4A nuclear receptors are tumor suppressors of AML that function in part through t

196 of a combinatorial library of oncogenes and tumor suppressors on cell growth.

197 teins to bind and degrade the retinoblastoma tumor suppressor or activate E2F target gene expression.

198 e, PA2G4 can function either as a contextual tumor suppressor or as an oncogene, depending on the tis

199 sponse, as concomitant deletion of the Trp53 tumor suppressor or Chek2 DNA damage checkpoint kinase r

200 ifies how the molecular context dictates the tumor suppressor or oncogenic function played by miRNAs.

201 The tumor suppressors p16 (CDKN2A) and p15 (CDKN2B) (encoded

202 h cell cycle arrest at G2/M, upregulation of tumor suppressor p53 and p21 protein.

203 The master tumor suppressor p53 controls transcription of a wide-ra

204 increased acetylation and protection of the tumor suppressor p53 from degradation.

205 The tumor suppressor p53 transcriptionally activates target

206 the disordered transactivation domain of the tumor suppressor p53, alpha-synuclein, and folded ubiqui

207 MDM2 and MDMX, negative regulators of the tumor suppressor p53, can work separately and as a heter

208 igh-risk E6-E6AP complex are known, e.g. the tumor suppressor p53, potential substrates of the low-ri

209 Cell stress and DNA damage activate the tumor suppressor p53, triggering transcriptional activat

210 a MAP kinase pathway or inactivation of the tumor suppressor p53, two alterations that occur in a la

211 activated, many of them directed towards the tumor suppressor p53, which coordinates the DNA damage r

212 the cell cycle checkpoint kinase MK2 and the tumor suppressor p53.

213 nd interaction partner Mdm2, antagonizes the tumor suppressor p53.

214 The tumor-suppressor p53 is a critical regulator of the cell

215 nd one of two versions of a functional human tumor suppressor, p53, fused to a far-red fluorescent pr

216 strating that the Parkinson disease gene and tumor suppressor Parkin bound and ubiquitinated PHGDH.

217 growth and survival when the upstream Hippo tumor suppressor pathway is silenced, but efforts to pha

218 Telomere shortening is a presumed tumor suppressor pathway that imposes a proliferative ba

219 ancer by promoting the activity of the Hippo tumor suppressor pathway, highlighting YAP and TAZ, Hipp

220 and thereby promoting activity of the Hippo tumor suppressor pathway.

221 the survival of GBM stem cells by repressing tumor suppressor pathways.

222 n of functionally intact fitness-sensing and tumor-suppressor pathways, whereas those with mutations

223 eas others do so by subverting senescence or tumor-suppressor pathways.

224 transformation that is due to subversion of tumor-suppressor pathways.

225 e-wide loss-of-function screen revealed that tumor suppressor PPP2R2A, a B regulatory subunit of prot

226 The retinoblastoma tumor suppressor protein (RB) plays an important role in

227 control, Cdks inactivate the retinoblastoma tumor suppressor protein (Rb) through phosphorylation, w

228 The p53 tumor suppressor protein is a potent activator of prolif

229 The p53 tumor suppressor protein is a transcription factor and m

230 The adenomatous polyposis coli (APC) tumor suppressor protein is associated with the regulati

231 The tumor suppressor protein p53 is critical for cell fate d

232 3-3 with the recognition motif of either the tumor suppressor protein p53 or the oncogenic transcript

233 MDMX have been reported as activators of the tumor suppressor protein p53 with therapeutic potential.

234 The tumor suppressor protein phosphatase 2A (PP2A) is a seri

235 AM and SH3 domain-containing protein 1) is a tumor suppressor protein that has roles in key cellular

236 The tumor suppressor protein TP53 (p53) plays a multifaceted

237 Here we identify the tumor suppressor Protein tyrosine phosphatase receptor-t

238 SMARCB1 has also been recognized to be a tumor suppressor protein which controls many tumorigenic

239 E-cadherin is a tumor suppressor protein, and the loss of its expression

240 (Cip1) cyclin-dependent kinase inhibitor and tumor suppressor protein.

241 de exchange factor, and are regulated by the tumor-suppressor protein APC.

242 The tumor-suppressor protein p53 is mutated in approximately

243 e propose that WASp functions as a putative "tumor-suppressor" protein in normal T and B cells, and "

244 entify a new role for these well-established tumor suppressor proteins at an early stage of the cellu

245 bor a high prevalence of pDGVs that truncate tumor suppressor proteins.

246 increase in biosynthesis of miR-21-regulated tumor suppressor proteins.

247 s responsible for the nuclear export of many tumor-suppressor proteins and viral ribonucleoproteins.

248 Tumor suppressor PTEN (phosphatase and tensin homologue

249 paper 'Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs' (Ta

250 Inactivation of the tumor suppressor PTEN has been shown to induce the EMT,

251 Quantification of the tumor suppressor PTEN in Colo-205 cells by immuno-MRM an

252 The tumor suppressor PTEN is essential for early development

253 formation induced by loss of function of the tumor suppressor Pten.

254 Intronic miR-374b and miR-545 inhibited tumor suppressors PTEN and RIG-I to enhance proto-oncoge

255 While the loss of the tumor suppressor, PTEN (phosphatase and tensin homolog),

256 Loss of the tumor suppressor, PTEN, is one of the most common findin

257 HPV E7 binds the putative tumor suppressor PTPN14 and targets it for degradation u

258 Insights into the role of the tumor suppressor pVHL in oxygen sensing motivated the te

259 A Ras GTPase activating protein tumor suppressor (RasGAP), DAB2 interacting protein (DAB

260 n CHT7 and the C. reinhardtii retinoblastoma tumor suppressor (RB) protein homolog MAT3.

261 cancer induced by germline mutations in the tumor suppressors RB1 or DICER1.

262 Given the role of TGFbeta1 as a tumor suppressor, reduced epithelial TGFbeta1 activity a

263 apoptosis regulators such as BCl-xL and the tumor suppressor retinoblastoma-associated protein 1 (RB

264 reatic cancer suggesting a haploinsufficient tumor suppressor role for BAP1.

265 Our studies provide evidence for a tumor suppressor role of GLS2 in certain types of cancer

266 ce article, Ramos et al. demonstrate a novel tumor-suppressor role of the circadian transcription fac

267 eported to be frequently deleted, implying a tumor-suppressor role.

268 anscription factor IRF-1, a well-established tumor suppressor, selectively attenuates MHV68-driven ge

269 number of genes are bona fide oncogenes and tumor suppressors such as Ras, Myc, beta-catenin, p53, a

270 rosis complex (TSC) is an autosomal dominant tumor suppressor syndrome, characterized by tumor develo

271 lishes a functional link between oncomiR-31, tumor suppressor target EGLN3, and up-regulated NF-kappa

272 Retinoblastoma protein (Rb) is a tumor suppressor that binds and represses E2F transcript

273 protein-coupled receptor B1 (BAI1/ADGRB1), a tumor suppressor that controls p53 stability by blocking

274 PTEN is a frequently mutated tumor suppressor that has been linked to the PTEN hamart

275 clude that TINF2 acts as a haploinsufficient tumor suppressor that limits telomere length to ensure a

276 Thus, DDX3X is a medulloblastoma tumor suppressor that regulates hindbrain development an

277 Our results suggest that HPK1 is a tumor suppressor that targets AXL for degradation via th

278 MEIS proteins are putative tumor suppressors that are frequently silenced in aggres

279 Despite harboring mutations in oncogenes and tumor suppressors that promote cancer growth, T-cell acu

280 maintaining high levels of transcription of tumor suppressors that promote cell death.

281 Unlike most tumor suppressors, they are rarely mutated/deleted, but

282 tumor tissue may explain AMPK switching from tumor suppressor to activator during tumor evolution.

283 The switch of p53 from tumor suppressor to oncogene is location-dependent and i

284 BMI1 represses tumor suppressors to promote cell proliferation, epithel

285 Mutations in the tumor suppressor TP53 are rare in renal cell carcinomas.

286 V16) E7 has long been known to stabilize the tumor suppressor TP53.

287 on and function of the most commonly mutated tumor suppressor, TP53, in the naked mole-rat.

288 Specific deletion of the tumor suppressor TRAF3 from B lymphocytes in mice leads

289 Loss of the tumor suppressor tuberous sclerosis complex 1 (Tsc1) in

290 monstrate for the first time that p190A is a tumor suppressor using a xenograft mouse model with carc

291 he oncoprotein Mdm2 can bind directly to the tumor suppressor VHL, and conjugate nedd8 to VHL within

292 ions in VHL, which encodes von Hippel-Lindau tumor suppressor (VHL), are associated with divergent di

293 a central regulator of organ size and a key tumor suppressor via coordinating cell proliferation and

294 To identify candidate tumor suppressors we applied CRISPR/Cas9 gene inactivati

295 To investigate BCOR as a putative tumor suppressor, we used a genetically engineered mouse

296 p16(INK4a) (CDKN2A) is a central tumor suppressor, which induces cell-cycle arrest and se

297 ve identified Rig-G as a novel and important tumor suppressor, which may serve as a potential therape

298 amide (HMBA) Induced Protein 1 (HEXIM1) as a tumor suppressor whose expression is decreased in breast

299 he REDD1-mediated stress response as a novel tumor suppressor whose loss defines a RAS mutant tumor s

300 ly characterized epigenetic modulating ccRCC tumor-suppressor with a marked impact on survival, was f